Skip to main content
Top
Published in: Familial Cancer 1/2010

01-03-2010

Childhood predictive genetic testing for Li–Fraumeni syndrome

Authors: D. G. Evans, P. Lunt, T. Clancy, R. Eeles

Published in: Familial Cancer | Issue 1/2010

Login to get access

Abstract

Presymptomatic genetic testing in childhood for adult onset conditions is generally discouraged as it does not directly benefit the child and removes their autonomy. In certain cancer prone conditions such as Familial Adenomatous Polyposis and Von Hippel Lindau disease there are risks of disease in childhood and benefit to children not inheriting a mutation in being able to forego unpleasant screening tests. Li–Fraumeni syndrome caused by constitutional TP53 mutations there are also implications in childhood with a risk of around 20% of a childhood malignancy. However, as yet no evidence based surveillance programme has been identified. We describe our experience of childhood testing for four children in two Li–Fraumeni families caused by TP53 mutations.
Literature
1.
go back to reference Li FP, Fraumeni JF (1969) Jr Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752PubMed Li FP, Fraumeni JF (1969) Jr Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752PubMed
2.
go back to reference Lynch T, Krush AJ, Harlan WL, Sharp EA (1973) Association of soft tissue sarcoma, leukemia and brain tumors in families affected with breast cancer. Am Surg 39:199–206PubMed Lynch T, Krush AJ, Harlan WL, Sharp EA (1973) Association of soft tissue sarcoma, leukemia and brain tumors in families affected with breast cancer. Am Surg 39:199–206PubMed
5.
go back to reference Birch JM, Hartley AL, Marsden HB et al (1984) Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 49:325–331PubMed Birch JM, Hartley AL, Marsden HB et al (1984) Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 49:325–331PubMed
7.
go back to reference Birch JM, Hartley AL, Blair V et al (1990) Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J Clin Oncol 8:583–590PubMed Birch JM, Hartley AL, Blair V et al (1990) Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J Clin Oncol 8:583–590PubMed
8.
go back to reference Strong LC, Stine M, Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213–1220PubMed Strong LC, Stine M, Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213–1220PubMed
10.
11.
go back to reference Birch JM, Hartley AL, Tricker J et al (1994) Prevalence and diversity of constitutional Mutations in the p53 Gene among 21 Li–Fraumeni Families. Cancer Res 54:1298–1304PubMed Birch JM, Hartley AL, Tricker J et al (1994) Prevalence and diversity of constitutional Mutations in the p53 Gene among 21 Li–Fraumeni Families. Cancer Res 54:1298–1304PubMed
12.
go back to reference Frebourg T, Barbier N, Yan Y-X et al (1995) Germ-line p53 Mutations in 15 Families with Li–Fraumeni Syndrome. Am J Hum Genet 56:608–615PubMed Frebourg T, Barbier N, Yan Y-X et al (1995) Germ-line p53 Mutations in 15 Families with Li–Fraumeni Syndrome. Am J Hum Genet 56:608–615PubMed
14.
go back to reference Varley JM, McGown G, Thorncroft M et al (1997) Germ-line mutations of TP53 in Li–Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252PubMed Varley JM, McGown G, Thorncroft M et al (1997) Germ-line mutations of TP53 in Li–Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252PubMed
16.
go back to reference Lalloo F, Varley J, Ellis D, O’Dair L, Pharoah P (2003) Evans DGR and the early onset breast cancer study Group. Family history is predictive of pathogenic mutations in BRCA1, BRCA2 and TP53 with high penetrance in a population based study of very early onset breast cancer. Lancet 361:1101–1102. doi:10.1016/S0140-6736(03)12856-5 CrossRefPubMed Lalloo F, Varley J, Ellis D, O’Dair L, Pharoah P (2003) Evans DGR and the early onset breast cancer study Group. Family history is predictive of pathogenic mutations in BRCA1, BRCA2 and TP53 with high penetrance in a population based study of very early onset breast cancer. Lancet 361:1101–1102. doi:10.​1016/​S0140-6736(03)12856-5 CrossRefPubMed
17.
go back to reference Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li–Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63(20):6643–6650PubMed Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li–Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63(20):6643–6650PubMed
20.
go back to reference Varley JM, Evans DGR, Birch JM (1997) Li–Fraumeni syndrome—a molecular and clinical review. Br J Cancer 76(1):1–14PubMed Varley JM, Evans DGR, Birch JM (1997) Li–Fraumeni syndrome—a molecular and clinical review. Br J Cancer 76(1):1–14PubMed
21.
go back to reference Evans DGR, Morrison P (2004) The ethical and insurance issues in testing for cancer -predisposition genes. In: Eeles R, Ponder B, Easton D, Eng C, Horwich A (eds) Genetic predisposition to cancer, 2nd edn. Chapman and Hall, London, pp 414–423 Evans DGR, Morrison P (2004) The ethical and insurance issues in testing for cancer -predisposition genes. In: Eeles R, Ponder B, Easton D, Eng C, Horwich A (eds) Genetic predisposition to cancer, 2nd edn. Chapman and Hall, London, pp 414–423
25.
go back to reference Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008) F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li–Fraumeni syndrome. JAMA 299(11):1315–1319. doi:10.1001/jama.299.11.1315 CrossRefPubMed Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008) F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li–Fraumeni syndrome. JAMA 299(11):1315–1319. doi:10.​1001/​jama.​299.​11.​1315 CrossRefPubMed
26.
go back to reference Evans DGR, Birch JM, Ramsden RT, Moffat D, Baser ME (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet 43(4):289–294. doi:10.1136/jmg.2005.036319 CrossRefPubMed Evans DGR, Birch JM, Ramsden RT, Moffat D, Baser ME (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet 43(4):289–294. doi:10.​1136/​jmg.​2005.​036319 CrossRefPubMed
Metadata
Title
Childhood predictive genetic testing for Li–Fraumeni syndrome
Authors
D. G. Evans
P. Lunt
T. Clancy
R. Eeles
Publication date
01-03-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9245-9

Other articles of this Issue 1/2010

Familial Cancer 1/2010 Go to the issue

OriginalPaper

Introduction

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine